Aerosol Delivery Devices Market Report by Product (Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers), Application (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Non-Respiratory Diseases), Distribution Channel (Retail Pharmac

Aerosol Delivery Devices Market Report by Product (Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers), Application (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Non-Respiratory Diseases), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Stores), and Region 2024-2032


The global aerosol delivery devices market size reached US$ 47.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 73.4 Billion by 2032, exhibiting a growth rate (CAGR) of 4.9% during 2024-2032.

Aerosol delivery devices are used in drug delivery and treating respiratory disorders, such as asthma, obstructive lung diseases, cystic fibrosis, pulmonary arterial hypertension, infectious pulmonary. They lower dosage requirements, reduce systemic adverse effects and improve the ability of patients to self-administer medication. Some of the commonly available aerosol delivery devices are pressurized metered-dose inhalers, nebulizers, and valved holder chambers. At present, smart aerosol drug delivery devices are used in non-respiratory conditions, such as diabetes, analgesia, thyroid disorders, and genetic diseases, due to the advent of novel macromolecular medications.

Aerosol Delivery Devices Market Trends:
The global outbreak of the coronavirus disease (COVID-19) that leads to acute respiratory infections among patients represents one of the key factors driving the need for aerosol delivery devices. These devices assist in treating obstructive airway diseases at home and in healthcare settings. Apart from this, the rising prevalence of chronic respiratory infections due to surging air pollution levels, allergens and occupational risks, and the increasing number of individuals who smoke tobacco and drink is propelling the market growth. Moreover, a considerable rise in the geriatric population, which is more vulnerable to developing serious health illnesses, is positively influencing the demand for portable inhalation devices that are convenient and economical. Besides this, market players are developing novel aerosol delivery devices that help treat chronic inflammation and infection in the lungs and improve airway clearance in patients with cystic fibrosis (CF). Furthermore, they are offering mini ultrasonic nebulizers and inhalers through e-commerce channels that have automatic memory and are easy to use while traveling. This, in confluence with the escalating demand for personalized drug therapy and the increasing use of online channels for purchasing medical supplies, is driving the market.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global aerosol delivery devices market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, application and distribution channel.

Breakup by Product:

Dry Powder Inhalers
Single Dose Inhalers
Multi Dose Inhalers
Metered Dose Inhalers
Conventional Pressurized Inhalers
Soft Mist Inhalers
Nebulizers
Jet Nebulizers
Ultrasonic Wave Nebulizers
Vibrating Mesh Nebulizers

Breakup by Application:

Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Cystic Fibrosis
Non-Respiratory Diseases
Diabetes
Analgesia
Parkinson’s Disease

Breakup by Distribution Channel:

Retail Pharmacies
Hospital Pharmacies
Online Stores

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Aerogen, GlaxoSmithKline plc, Johnson & Johnson, Koninklijke Philips N.V., Merck & Co. Inc., Metall Zug AG, Recipharm AB (publ), Teva Pharmaceutical Industries Ltd. and Vectura Group plc.

Key Questions Answered in This Report

1. What was the size of the global aerosol delivery devices market in 2023?
2. What is the expected growth rate of the global aerosol delivery devices market during 2024-2032?
3. What are the key factors driving the global aerosol delivery devices market?
4. What has been the impact of COVID-19 on the global aerosol delivery devices market?
5. What is the breakup of the global aerosol delivery devices market based on the product?
6. What is the breakup of the global aerosol delivery devices market based on the distribution channel?
7. What are the key regions in the global aerosol delivery devices market?
8. Who are the key players/companies in the global aerosol delivery devices market?


1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Aerosol Delivery Devices Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Product
6.1 Dry Powder Inhalers
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 Single Dose Inhalers
6.1.2.2 Multi Dose Inhalers
6.1.3 Market Forecast
6.2 Metered Dose Inhalers
6.2.1 Market Trends
6.2.2 Key Segments
6.2.2.1 Conventional Pressurized Inhalers
6.2.2.2 Soft Mist Inhalers
6.2.3 Market Forecast
6.3 Nebulizers
6.3.1 Market Trends
6.3.2 Key Segments
6.3.2.1 Jet Nebulizers
6.3.2.2 Ultrasonic Wave Nebulizers
6.3.2.3 Vibrating Mesh Nebulizers
6.3.3 Market Forecast
7 Market Breakup by Application
7.1 Asthma
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Chronic Obstructive Pulmonary Disease (COPD)
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Cystic Fibrosis
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Non-Respiratory Diseases
7.4.1 Market Trends
7.4.2 Key Segments
7.4.2.1 Diabetes
7.4.2.2 Analgesia
7.4.2.3 Parkinson’s Disease
7.4.3 Market Forecast
8 Market Breakup by Distribution Channel
8.1 Retail Pharmacies
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Hospital Pharmacies
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Online Stores
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 3M Company
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Aerogen
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.3 GlaxoSmithKline plc
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Johnson & Johnson
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 Koninklijke Philips N.V.
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 Merck & Co. Inc.
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 Metall Zug AG
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.8 Recipharm AB (publ)
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.9 Teva Pharmaceutical Industries Ltd.
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.9.4 SWOT Analysis
14.3.10 Vectura Group plc
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.10.4 SWOT Analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings